Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer.
about
Advances in genetics: widening our understanding of prostate cancerMisfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer.OTUB1 de-ubiquitinating enzyme promotes prostate cancer cell invasion in vitro and tumorigenesis in vivo.Multi-transcript profiling in archival diagnostic prostate cancer needle biopsies to evaluate biomarkers in non-surgically treated men.Expression of ERG protein in prostate cancer: variability and biological correlates.Partial PTEN deletion is linked to poor prognosis in breast cancer8p deletion is strongly linked to poor prognosis in breast cancer.Expression of SOCS1 and the downstream targets of its putative tumor suppressor functions in prostate cancer.Three-dimensional disorganization of the cancer genome occurs coincident with long-range genetic and epigenetic alterations.Evidence of a prion-like transmission of p53 amyloid in Saccharomyces cerevisiae.Alterations in Three-Dimensional Organization of the Cancer Genome and Epigenome.A role for the dehydrogenase DHRS7 (SDR34C1) in prostate cancer.Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?Qualitative and Quantitative Requirements for Assessing Prognostic Markers in Prostate Cancer.Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer.Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer.Exploring prostate cancer genome reveals simultaneous losses of PTEN, FAS and PAPSS2 in patients with PSA recurrence after radical prostatectomy.Deletion of 8p is an independent prognostic parameter in prostate cancer.Deletion of 18q is a strong and independent prognostic feature in prostate cancerC10orf116 Gene Copy Number Loss in Prostate Cancer: Clinicopathological Correlations and Prognostic Significance.The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas?Combined Loss of EAF2 and p53 Induces Prostate Carcinogenesis in Male Mice.Androgen induces G3BP2 and SUMO-mediated p53 nuclear export in prostate cancer.Analytic, Preanalytic, and Clinical Validation of p53 IHC for Detection of TP53 Missense Mutation in Prostate Cancer.Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.EAF2 and p53 Co-Regulate STAT3 Activation in Prostate Cancer.Exogenous IL6 induces mRNA splice variant MBD2_v2 to promote stemness in TP53 wild-type, African American PCa cells.Analysis of differentially expressed genes, clinical value and biological pathways in prostate cancer.Improving adenoviral vectors and strategies for prostate cancer gene therapy
P2860
Q26740628-368238FA-40BC-4DAA-A3F4-BE9E33C4BDB5Q30374671-7799B59D-A02E-44FF-83BA-2E3AF79F0082Q35061299-5B231D78-351C-4DB3-AFF0-7E8E2767D4F7Q35256915-D5AFA312-4FC3-4059-8C9B-E63E9E148D0FQ35608000-1A7F3027-E7CA-4DA1-A3CE-180053A3F870Q35870069-1B83543E-719D-4111-BA67-00A0085C1944Q36214952-A1A45F3A-4A67-4929-A473-256DF2705216Q36290408-4BD467E9-AE27-4E6E-A4F5-13488A7F11F1Q36959187-E1A32AD9-D34D-4532-9B5E-D13BEF862EE4Q38718360-417C3269-6768-4F69-8061-31C9E67CD023Q38829665-738886BF-AFB2-46FF-995A-C2168544F66EQ38840506-5DC4D1CD-A695-48CE-A7CC-C13EF1286D5BQ38934098-9FECAF4E-D7BB-47A2-BC8A-1092244B666AQ39417832-F5C7C165-771D-46B6-AAFC-F80B4DD530CFQ40622027-3ADD81D4-9FC4-4BCC-A331-22A81D52AA3CQ40903462-B627A68B-067F-41D7-A7C0-ABD393187B6CQ41439657-EEC1E36C-0549-4C57-BFE5-D69ED5E6E4EAQ42043270-D4EBC4B1-E8CB-4A92-8A03-91B54C78CF21Q42316509-B63B6C71-5F45-4B12-92ED-2ABAD5F0DEC6Q43119437-0514A384-3D17-4E36-9158-3A47AFBD8967Q47379977-4A362BB9-A053-42D7-ADE5-1D08A09B5BC5Q47657085-E899F24A-3804-4E63-9CEA-A4F5D50C3B1DQ48152470-492C2F68-D921-4026-A293-806157CD1452Q51033341-D53B1EDB-1504-4942-8C67-6EC93221FB56Q51350568-5C5F8975-334D-4ECD-8EC7-050030270E1DQ52666493-C58FEA43-A194-45E2-87DB-A1656A85E0D3Q53684369-9324B79F-1E2F-44F9-BDDB-51513906CF4AQ55004153-3238F156-0D01-4A0D-BF64-FDF313FD9188Q58801177-F7AC8AB6-C392-4091-88F0-2D62297541AC
P2860
Clinical significance of different types of p53 gene alteration in surgically treated prostate cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Clinical significance of diffe ...... cally treated prostate cancer.
@en
Clinical significance of diffe ...... cally treated prostate cancer.
@nl
type
label
Clinical significance of diffe ...... cally treated prostate cancer.
@en
Clinical significance of diffe ...... cally treated prostate cancer.
@nl
prefLabel
Clinical significance of diffe ...... cally treated prostate cancer.
@en
Clinical significance of diffe ...... cally treated prostate cancer.
@nl
P2093
P2860
P356
P1476
Clinical significance of diffe ...... cally treated prostate cancer.
@en
P2093
Alexander Haese
Alexander Quaas
Antje Krohn
Christina Koop
Guido Sauter
Hartwig Huland
Jan Korbel
Jovisa Gjoni
Julia Hühne-Simon
Katharina Grupp
P2860
P304
P356
10.1002/IJC.28784
P577
2014-04-26T00:00:00Z